Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background And Hypothesis: Antipsychotics are first-line drug treatments for schizophrenia. When antipsychotic monotherapy is ineffective, combining two antipsychotic drugs is common although treatment guidelines warn of possible increases in side effects. Risks of metabolic side effects with antipsychotic polypharmacy have not been fully investigated. This study examined associations between antipsychotic polypharmacy and risk of developing diabetes, hypertension, or hyperlipidemia in adults with schizophrenia, and impact of co-prescription of first- and second-generation antipsychotics.

Study Design: A population-based prospective cohort study was conducted in the United Kingdom using linked primary care, secondary care, mental health, and social deprivation datasets. Cox proportional hazards models with stabilizing weights were used to estimate risk of metabolic disorders among adults with schizophrenia, comparing patients on antipsychotic monotherapy vs polypharmacy, adjusting for demographic and clinical characteristics, and antipsychotic dose.

Study Results: Median follow-up time across the three cohorts was approximately 14 months. 6.6% developed hypertension in the cohort assembled for this outcome, with polypharmacy conferring an increased risk compared to monotherapy, (adjusted Hazard Ratio = 3.16; P = .021). Patients exposed to exclusive first-generation antipsychotic polypharmacy had greater risk of hypertension compared to those exposed to combined first- and second-generation polypharmacy (adjusted HR 0.29, P = .039). No associations between polypharmacy and risk of diabetes or hyperlipidemia were found.

Conclusions: Antipsychotic polypharmacy, particularly polypharmacy solely comprised of first-generation antipsychotics, increased the risk of hypertension. Future research employing larger samples, follow-up longer than the current median of 14 months, and more complex methodologies may further elucidate the association reported in this study.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919771PMC
http://dx.doi.org/10.1093/schbul/sbad126DOI Listing

Publication Analysis

Top Keywords

antipsychotic polypharmacy
16
antipsychotic
9
polypharmacy
9
risk metabolic
8
metabolic disorders
8
antipsychotic monotherapy
8
side effects
8
polypharmacy risk
8
adults schizophrenia
8
first- second-generation
8

Similar Publications

Background: The objective of this study was to characterize real-world prescription patterns of antipsychotic drugs in patients with various psychiatric disorders with psychotic features.

Method: We analyzed the discharge prescription plans of 59,962 cases with the main diagnoses schizophrenia, schizoaffective disorder, acute transient psychotic disorder, delusional disorder, psychotic bipolar disorder, psychotic depression, organic delusional disorder or substance-induced psychosis. We analyzed the overall use, pharmacological subgroups, the use of long-acting injectable (LAI) formulations, and the frequency of prescription of the singular antipsychotic drugs.

View Article and Find Full Text PDF

Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal condition characterized by hyperthermia, severe muscle rigidity, altered mental status, and autonomic dysfunction, associated with dopamine D₂-receptor antagonists. We present the case of a 76-year-old institutionalized male with multiple comorbidities who developed NMS four days after initiating quetiapine, following recent discontinuation of risperidone. The clinical picture included hyperthermia, generalized rigidity, trismus, disorientation, autonomic instability, leukocytosis, hypernatremia, and markedly elevated creatine kinase.

View Article and Find Full Text PDF

Association of neonatal withdrawal syndrome with concurrent use of multiple neuropsychiatric medications in pregnant women.

Early Hum Dev

August 2025

Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Ten-nodai, Tsukuba, Ibaraki 305-8575, Japan; Department of Pharmacy, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 305-8576, Japan.

Aim: Neonatal withdrawal syndrome is characterized by withdrawal symptoms in neonates because of the discontinuation of transplacental drug transfer after delivery. This study aimed to examine the risk factors for withdrawal symptoms to clarify the impact of the number of neuropsychiatric drugs administered during pregnancy.

Methods: This was a retrospective observational study including 344 neonates born to 341 mothers receiving neuropsychiatric drugs, including antipsychotics, antidepressants, antiepileptics, and anxiolytics/sedatives during pregnancy.

View Article and Find Full Text PDF

Antipsychotic polypharmacy (APP) remains common in the treatment of schizophrenia despite increased risk of adverse events and limited evidence of additional efficacy compared to antipsychotic monotherapy (APM). We conducted a nationwide, register-based cohort study to characterize APP among patients with schizophrenia in Denmark, 1997-2021. Patients were followed from year 3 after the schizophrenia diagnosis and onwards.

View Article and Find Full Text PDF

Aripiprazole is a third-generation antipsychotic, approved in 2002, notable for its partial agonism of the Dopamine D2 receptor and lower risk of metabolic and extrapyramidal adverse effects. It is available in a long-acting injectable formulation, which is very useful for maintaining medication compliance, which is crucial for preventing recurrent psychotic episodes in patients. Additionally, the aripiprazole long-acting injectable is frequently combined with other antipsychotic medications in acute settings to manage refractory symptoms.

View Article and Find Full Text PDF